Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival: Clinical trial

A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.

Leave A Comment

Your email address will not be published. Required fields are marked *